Skip to main content
Download PDF
Download ePub

Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Harm Reduction Journal volume 20, Article number: 170 (2023) Cite this article

The Original Article was published on 30 September 2023

Correction : Harm Reduction Journal (2023) 20:1 https://doi.org/10.1186/s12954-023-00879-7

In the original version of this article [1], the paragraph under the section “Drug War Failure” should read as follows:

Xylazine is unscheduled at the federal level, and to date is illegal only in Florida, where it was banned in 2018 [40]. Increased attention to xylazine and its harms has recently prompted a call for xylazine to be federally scheduled. However, we urge caution in such an approach. Scheduling xylazine would only control the licit supply, creating barriers to needed research on the health impacts, toxicology, and safety profile of the drug. Further, xylazine is used very commonly as a surgical anesthetic for animals used in pre-clinical research, including cancer research. Scheduling xylazine would disrupt these research areas and slow progress.

The original article has been corrected.

Reference

  1. Zagorski CM, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20:141. https://doi.org/10.1186/s12954-023-00879-7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1910, PHR 3.208J, Austin, TX, 78712, USA

    Claire M. Zagorski & Lucas G. Hill

  2. HIV Prevention Research Division, Department of Psychiatry, School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 4000, Philadelphia, PA, 19104, USA

    Rebecca A. Hosey

  3. Narcomedia, Inc., Philadelphia, PA, USA

    Christopher Moraff

  4. National Survivors Union, 1116 Grove St, Greensboro, NC, 27403, USA

    Aaron Ferguson

  5. Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, 135 Dauer Drive, Chapel Hill, NC, 27599, USA

    Mary Figgatt

  6. University of Pennsylvania School of Nursing, Fagin Hall, 418 Curie Blvd, Philadelphia, PA, 19104, USA

    Shoshana Aronowitz

  7. Greater Lawrence Family Health Center, 34 Haverhill Street, Lawrence, MA, 01841, USA

    Natalie E. Stahl

  8. Department of Pharmacology, Bowles Center for Alcohol Studies, University of North Carolina, CB#7178, 104 Manning Road, Chapel Hill, NC, 2759, USA

    Zoe McElligott

  9. University of North Carolina, 725 MLK Jr. Blvd., CB 7505, Chapel Hill, NC, 27599, USA

    Nabarun Dasgupta

Authors
  1. Claire M. Zagorski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca A. Hosey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher Moraff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aaron Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mary Figgatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shoshana Aronowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Natalie E. Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lucas G. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zoe McElligott
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nabarun Dasgupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire M. Zagorski.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zagorski, C.M., Hosey, R.A., Moraff, C. et al. Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J 20, 170 (2023). https://doi.org/10.1186/s12954-023-00903-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12954-023-00903-w

Harm Reduction Journal

ISSN: 1477-7517